Video wird geladen...

Video konnte nicht geladen werden

Beim Laden dieses Videos ist ein Problem aufgetreten. Dies könnte an einem vorübergehenden Netzwerkproblem liegen oder das Video ist möglicherweise nicht verfügbar.

GLP-1s are revolutionary drugs. Access isn't the problem. Affordability and adherence are. eMed scales access to GLP-1s at affordable pricing, so employers can finally cover them. AI plus clinical support. 90% adherence. Real outcomes. We're not a prescription pad. We're a support system.

Linda Yaccarino

779,461 subscribers

26,350 Aufrufe • vor 1 Monat •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

When adherence is maintained with GLP-1 medications, health outcomes improve and financial outcomes follow. At eMed we are seeing a high adherence rate - the result of a structured program that drives results. Grateful to Arianna Huffington and Brooke Green of Aon for a conversation every employer needs to hear right now

When adherence is maintained with GLP-1 medications, health outcomes improve and financial outcomes follow. At eMed we are seeing a high adherence rate - the result of a structured program that drives results. Grateful to Arianna Huffington and Brooke Green of Aon for a conversation every employer needs to hear right now

Linda Yaccarino

14,328 Aufrufe • vor 4 Monaten

Last week on Fox Business with Maria Bartiromo, alongside Tom Brady, we announced our $200M Series A at a $2B+ valuation. We’re building how healthcare should actually work. For employers: better adherence, better outcomes, lower total cost. GLP-1s only work if people stay on them. We solve that at eMed. DMs open. 📩

Last week on Fox Business with Maria Bartiromo, alongside Tom Brady, we announced our $200M Series A at a $2B+ valuation. We’re building how healthcare should actually work. For employers: better adherence, better outcomes, lower total cost. GLP-1s only work if people stay on them. We solve that at eMed. DMs open. 📩

Linda Yaccarino

33,741 Aufrufe • vor 5 Monaten

1 in 10 people globally interact with AI weekly. 1 IN 8 AMERICANS ARE ON A GLP-1. Finally, healthcare DEFLATION. While AI is reshaping how we do things, GLP-1s are reshaping human biology. And their convergence offers something the US healthcare system has never experienced in its entire history. As Eric Larsen points out, this is not a trend. This is a restructuring of humanity. eMed

1 in 10 people globally interact with AI weekly. 1 IN 8 AMERICANS ARE ON A GLP-1. Finally, healthcare DEFLATION. While AI is reshaping how we do things, GLP-1s are reshaping human biology. And their convergence offers something the US healthcare system has never experienced in its entire history. As Eric Larsen points out, this is not a trend. This is a restructuring of humanity. eMed

Linda Yaccarino

19,193 Aufrufe • vor 2 Monaten

A BIG moment for eMed. We've just raised $200M at a $2B+ valuation, and we're bringing on incredible investors and partners who believe deeply in what we're building. GLP-1s are one of the most powerful advances in medicine we've seen in humanity’s history . But they only work if people stay on them. We've built an empathic agentic AI platform that makes that happen, one that meets members where they are and guides them every step of the way. And the results speak for themselves. We're building the future of AI-powered population health. And we're just getting started. 🚀

A BIG moment for eMed. We've just raised $200M at a $2B+ valuation, and we're bringing on incredible investors and partners who believe deeply in what we're building. GLP-1s are one of the most powerful advances in medicine we've seen in humanity’s history . But they only work if people stay on them. We've built an empathic agentic AI platform that makes that happen, one that meets members where they are and guides them every step of the way. And the results speak for themselves. We're building the future of AI-powered population health. And we're just getting started. 🚀

Linda Yaccarino

31,662 Aufrufe • vor 5 Monaten

🚨 Da’Shaun L. Harrison at Socialism 2026 argues that the political deployment of GLP-1 drugs is “fascistic” because they exist in “a world fixated on genociding fat people.” “The political deployment of GLP-1s is fascistic, not because individuals take them, but because the conditions under which they become necessary are shaped by a world fixated on genociding fat people.” And to explain why that is supposedly fascistic, Harrison turns to Frantz Fanon and “Black flesh under colonial surveillance.” If GLP-1s are already “body fascism,” the dual and triple agonists are going to require an entirely new theoretical vocabulary.

🚨 Da’Shaun L. Harrison at Socialism 2026 argues that the political deployment of GLP-1 drugs is “fascistic” because they exist in “a world fixated on genociding fat people.” “The political deployment of GLP-1s is fascistic, not because individuals take them, but because the conditions under which they become necessary are shaped by a world fixated on genociding fat people.” And to explain why that is supposedly fascistic, Harrison turns to Frantz Fanon and “Black flesh under colonial surveillance.” If GLP-1s are already “body fascism,” the dual and triple agonists are going to require an entirely new theoretical vocabulary.

Stu Smith

3,995,925 Aufrufe • vor 10 Tagen

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 Aufrufe • vor 1 Jahr

🚨 LMAO! Socialists are now raging at the use of weight-loss drugs because it's "FASCISM" and "genociding fat people" "GLP-1s just mark a new phase in body fascism." 🤡 "The political deployment of GLP-1s is fascistic...because conditions under which they become necessary are shaped by a world fixated on genociding fat people." These people are allowed to vote, by the way. It's not fascist to say being fat is dangerous to your health! Normal people do NOT think like this!

🚨 LMAO! Socialists are now raging at the use of weight-loss drugs because it's "FASCISM" and "genociding fat people" "GLP-1s just mark a new phase in body fascism." 🤡 "The political deployment of GLP-1s is fascistic...because conditions under which they become necessary are shaped by a world fixated on genociding fat people." These people are allowed to vote, by the way. It's not fascist to say being fat is dangerous to your health! Normal people do NOT think like this!

Eric Daugherty

113,533 Aufrufe • vor 7 Tagen

Clavicular REVEALS he spent $30K buying directly from underground Chinese sources gave him early access to GLP-1s 😳👀 "This was like the OG LooksMax store... $7 for a vial of testosterone, $5 for a vial of Tren." "I literally spent like $30,000 on there. I had every single supplement, ancillary, every single roid..." "That's why I was so quick to GLP-1s, and I started taking them like before anyone else."

Clavicular REVEALS he spent $30K buying directly from underground Chinese sources gave him early access to GLP-1s 😳👀 "This was like the OG LooksMax store... $7 for a vial of testosterone, $5 for a vial of Tren." "I literally spent like $30,000 on there. I had every single supplement, ancillary, every single roid..." "That's why I was so quick to GLP-1s, and I started taking them like before anyone else."

S6BER

11,613 Aufrufe • vor 1 Monat

Bryan Johnson explains the benefits of Ozempic and how it can help solve food addiction “If you have a food addiction problem that's impossible to solve, a GLP-1 solves it. There are some side effects. For example, the dose I'm on raises my resting heart rate by two or three beats, which is a big deal for me, but the benefits are great. GLP-1s are the first legit longevity drugs” “I am as healthy as a person can be and I still benefit from GLP-1. It has metabolic effects and good neuroprotective effects. If you compare my blood glucose management to an 18 year old’s, I'm better than 99 out of 100 18 year olds”

Bryan Johnson explains the benefits of Ozempic and how it can help solve food addiction “If you have a food addiction problem that's impossible to solve, a GLP-1 solves it. There are some side effects. For example, the dose I'm on raises my resting heart rate by two or three beats, which is a big deal for me, but the benefits are great. GLP-1s are the first legit longevity drugs” “I am as healthy as a person can be and I still benefit from GLP-1. It has metabolic effects and good neuroprotective effects. If you compare my blood glucose management to an 18 year old’s, I'm better than 99 out of 100 18 year olds”

Mikli

447,184 Aufrufe • vor 6 Monaten

The Biden administration created a bailout for insurance companies. We ended it. The Trump Administration is focused on delivering real results: ✅Affordable plans: 90% + seniors will be able to access drug plans under $10/mo. ✅Lower drug prices: approximately 250,000 Medicare eligible beneficiaries have signed up to get affordable GLP-1s at just $50/mo., representing hundreds of dollars in monthly savings for seniors. ✅Protecting the integrity of Medicare: fighting for America’s seniors, not big insurance companies.

The Biden administration created a bailout for insurance companies. We ended it. The Trump Administration is focused on delivering real results: ✅Affordable plans: 90% + seniors will be able to access drug plans under $10/mo. ✅Lower drug prices: approximately 250,000 Medicare eligible beneficiaries have signed up to get affordable GLP-1s at just $50/mo., representing hundreds of dollars in monthly savings for seniors. ✅Protecting the integrity of Medicare: fighting for America’s seniors, not big insurance companies.

Dr. Oz CMS

25,102 Aufrufe • vor 1 Monat

David Sinclair: "Sudden blindness has doubled because of GLP-1 drugs." ROGAN: “Holy shit!” SINCLAIR: “It’s like a stroke in your eye. And then your other eye can go. And there’s nothing you can do about it.” ROGAN: “Obviously, correlation does not equal causation, but...” SINCLAIR: “Yeah, there’s a scientist at Harvard, Joseph Rizzo. It looks like it’s repeatable across the planet.” ROGAN: “Wow, that’s terrible because there are so many people out there telling everyone they should get on GLP-1s.” Joe Rogan David Sinclair

David Sinclair: "Sudden blindness has doubled because of GLP-1 drugs." ROGAN: “Holy shit!” SINCLAIR: “It’s like a stroke in your eye. And then your other eye can go. And there’s nothing you can do about it.” ROGAN: “Obviously, correlation does not equal causation, but...” SINCLAIR: “Yeah, there’s a scientist at Harvard, Joseph Rizzo. It looks like it’s repeatable across the planet.” ROGAN: “Wow, that’s terrible because there are so many people out there telling everyone they should get on GLP-1s.” Joe Rogan David Sinclair

KanekoaTheGreat

1,508,724 Aufrufe • vor 1 Monat

'We're seeing lifestyle-type drugs, Ozempic and steroids' HM Chief Inspector of Prisons Charlie Taylor tells Wilfred Frost that drones are an "enormous problem" in prisons because of the amount they can carry, giving prisoners access to a much wider range of drugs.

'We're seeing lifestyle-type drugs, Ozempic and steroids' HM Chief Inspector of Prisons Charlie Taylor tells Wilfred Frost that drones are an "enormous problem" in prisons because of the amount they can carry, giving prisoners access to a much wider range of drugs.

Ridge & Frost

27,878 Aufrufe • vor 2 Monaten

🚨 JD Vance gives the PERFECT answer Q: Why should voters not blame Trump for affordability? JD VANCE: "If you think inflation and affordability is a problem, we're doing everything we can to bring down prices. DEMOCRATS say they want to INCREASE taxes!" "TrumpRx has almost 800 medications...most significant reduction in drug costs in 60 years." "The Democrats did nothing." "While they're BRAGGING they'll reverse these policies...we're saying, we're gonna DOUBLE DOWN that'll make prescription drugs more affordable!" "They're gonna undo our very good efforts to bring down inflation and make it sustainable."

🚨 JD Vance gives the PERFECT answer Q: Why should voters not blame Trump for affordability? JD VANCE: "If you think inflation and affordability is a problem, we're doing everything we can to bring down prices. DEMOCRATS say they want to INCREASE taxes!" "TrumpRx has almost 800 medications...most significant reduction in drug costs in 60 years." "The Democrats did nothing." "While they're BRAGGING they'll reverse these policies...we're saying, we're gonna DOUBLE DOWN that'll make prescription drugs more affordable!" "They're gonna undo our very good efforts to bring down inflation and make it sustainable."

Eric Daugherty

43,519 Aufrufe • vor 13 Tagen

There's a class of drugs called PCSK9 inhibitors that few people have heard of but Alex thinks will be far bigger than GLP-1s (which is already one of the best selling drugs of all time). They were discovered through a population born with a genetic mutation that gives them an 88% lifetime reduction in cardiovascular disease risk. The drugs mimic that mutation, significantly lowering our bad cholesterol and reducing the risk of a future heart attack or stroke. Alex describes them as close to a free lunch as there is in biology. "Because it is more asymmetric, it is more of a free lunch, I would argue that this medicine should be far bigger in terms of the number of people that are on it and the revenues associated with it than GLP-1s."

There's a class of drugs called PCSK9 inhibitors that few people have heard of but Alex thinks will be far bigger than GLP-1s (which is already one of the best selling drugs of all time). They were discovered through a population born with a genetic mutation that gives them an 88% lifetime reduction in cardiovascular disease risk. The drugs mimic that mutation, significantly lowering our bad cholesterol and reducing the risk of a future heart attack or stroke. Alex describes them as close to a free lunch as there is in biology. "Because it is more asymmetric, it is more of a free lunch, I would argue that this medicine should be far bigger in terms of the number of people that are on it and the revenues associated with it than GLP-1s."

Patrick OShaughnessy

223,532 Aufrufe • vor 4 Monaten

Street homelessness and crime are down. Affordable housing is up. We're turning the page and making real progress after decades of inaction. Thank you so much to the more than 200 people who rallied in support of our campaign at our volunteer HQ opening!

Street homelessness and crime are down. Affordable housing is up. We're turning the page and making real progress after decades of inaction. Thank you so much to the more than 200 people who rallied in support of our campaign at our volunteer HQ opening!

Karen Bass

257,151 Aufrufe • vor 5 Monaten

Nick says fed-jacketing Patriot Front misses the real problem "I think it's sloppy and lazy to say they are 'feds.' I think that's a red herring and that's not my problem with them... I do not support so called 'street activism'"

Nick says fed-jacketing Patriot Front misses the real problem "I think it's sloppy and lazy to say they are 'feds.' I think that's a red herring and that's not my problem with them... I do not support so called 'street activism'"

S.clips

11,161 Aufrufe • vor 2 Monaten

Two days ago, we launched BIOS, our AI Scientist. Researchers are already using it to accelerate discovery. Access: → Researchers with .edu emails get immediate "Researcher" tier access (with 300 credits per month and the option to have 5 concurrent research runs) → Heavy users can purchase higher tiers via credit card → Soon: BIO token purchases at a discount We're monitoring system costs and may adjust pricing as usage scales. The economic loop: All revenue from BIOS (credit card + BIO purchases) flows into token buybacks. Researchers finding promising discoveries through BIOS will get active support for fundraising via the Bio Launchpad. Discovery generates revenue → revenue supports the protocol → protocol funds new discovery. Systems that compound.

Two days ago, we launched BIOS, our AI Scientist. Researchers are already using it to accelerate discovery. Access: → Researchers with .edu emails get immediate "Researcher" tier access (with 300 credits per month and the option to have 5 concurrent research runs) → Heavy users can purchase higher tiers via credit card → Soon: BIO token purchases at a discount We're monitoring system costs and may adjust pricing as usage scales. The economic loop: All revenue from BIOS (credit card + BIO purchases) flows into token buybacks. Researchers finding promising discoveries through BIOS will get active support for fundraising via the Bio Launchpad. Discovery generates revenue → revenue supports the protocol → protocol funds new discovery. Systems that compound.

clepp

31,095 Aufrufe • vor 7 Monaten